One-Year Trajectory of Cognitive Changes in Patients With Late-life Depression in the Short Term

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorFujian Medical University

About this trial

The purpose of this study was to investigate the one-year trajectory of cognitive change in elderly patients with depression, to explore the transfer characteristics and transfer rules of various states of cognitive impairment in patients, to predict the relevant risk factors of cognitive decline, and to find possible influencing factors affecting state change, so as to provide a theoretical basis and reference for subsequent targeted intervention research on geriatric depression.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

meeting the criteria for major depression in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

age at first onset ≥60 years

Informed consent

Disqualifiers

Relevant past history affecting cognitive function: various types of stroke, traumatic brain injury, severe brain atrophy, mental abnormalities

Perennial alcohol addiction, or long-term use of various drugs that affect mental state

Survival time of malignant tumors and tumors

Patients with language, vision, and hearing impairments

Trial population

Elderly patients with depression who met the inclusion and exclusion criteria were selected from a number of nursing facilities, hospitals and communities

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Montreal cognitive assessment scale (MoCA)

The Changsha version of the MoCA questionnaire was used in this study, which included eight cognitive assessments of visuospatial and executive functions, naming, memory, attention, speech, abstraction, delayed recall, and orientation, with a total score of 30, with higher scores indicating better cognitive functioning.

Time frame
2023.6.1-2024.8.1
2

Subjective cognitive decline questionnaire (SCD questionnaire 9, SCD-9)

The SCD-9 is mainly used to distinguish between normal people and SCD patients. The scale mainly consists of 2 dimensions, i.e., overall memory ability and time comparison (4 entries) and daily activity ability (5 entries), with a total of 9 entries, and the total scale score ranges from 0 to 9, with higher scores indicating a more severe degree of SCD.

Time frame
2023.6.1-2024.8.1

Secondary outcomes

1

Activities of Daily Living (ADL)

The Activities of Daily Living (ADL) scale adopts a Liket four level rating. The evaluation results can be analyzed based on total score, dimension score, and individual score. A total score of 20 is considered completely normal, while a score above 20 indicates varying degrees of functional decline. A score of 1 for each item indicates normal functionality, while a score of 2-4 indicates decreased functionality.

Time frame
2023.6.1-2024.8.1
2

general information

Using a self-made general information scale, such as age, gender, education level, and other basic personal information

Time frame
2023.6.1-2024.8.1
3

Self Rating Anxiety Scale (SAS)

The Self Rating Anxiety Scale (SAS) has a total of 20 items, of which 5, 9, 13, 17, and 19 items are scored in reverse. The scale adopts a 1-4 level scoring method (1 point for no or very little time; 2 points for a small portion of time; 3 points for a considerable amount of time; 4 points for the vast majority or all of time). Individuals fill in the scale based on their own situation in the most recent week, multiply the calculated total score by 1.25, take an integer as the standard score, and use it as a statistical indicator. The higher the standard score, the more severe the anxiety level of the individual.

Time frame
2023.6.1-2024.8.1
4

Social Support Rating Scale (SSRS)

The Social Support Rating Scale (SSRS) includes three dimensions: objective support, subjective support, and support utilization, with a total of 10 items: 1 point (none) to 4 points (full support). The higher the score in each dimension, the more support received.

Time frame
2023.6.1-2024.8.1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.